Skip to main content
Sign In

Clinical Trials

Aastrom Announces Collaboration with CPC Clinical Research for the Phase 3 REVIVE Study in Critical Limb Ischemia

ANN ARBOR, Mich., [May 25, 2011] - Aastrom Biosciences, Inc. (Nasdaq: ASTM), a leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced a collaborative agreement with CPC Clinical Research (CPC), a non-profit, Academic Research Organization led by William Hiatt, M.D. CPC will provide services related to the execution of Aastrom’s Phase 3 REVIVE clinical studies for ixmyelocel-T, the company’s expanded multicellular therapy. View full press release >>

A Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer: a Rational anti-CancerStem Cell Combination.

This is a research study of an investigational drug called IPI-926 used together with Cetuximab. The main goal of this research study is to test the safety and tolerability of the study drug in combination with cetuximab and to discover what side effects it has, whether good or bad, on you and your cancer. The study will determine the highest dose of the study drug that can be given to subjects without causing severe or life-threatening side effects.


  • For additional clinical trials being conducted on the University of Colorado Medical campus, see the Research Affairs page.  
  • For clinical trials being conducted nationally, please click here.
  • For help designing or managing multi-center clinical trials, see CPC Clinical Research.